Dual antiplatelet treatment (DAPT) is a cornerstone in the treatment of acute coronary syndrome (ACS) but the optimal treatment duration is unclear. We aimed to evaluate the effect of DAPT duration with clopidogrel and aspirin on the recurrence of ischaemic events and bleeding in a large, unselected ACS population.
Introduction
Dual antiplatelet treatment (DAPT) with aspirin and P2Y12 receptor inhibitor is recommended for patients with acute coronary syndrome (ACS) whether treated invasively or non-invasively. 1, 2 While no trial has supported extended DAPT, a treatment duration of 9-12 months after ACS and up to 12 months after drug-eluting stent placement are recommended by guidelines based on the design of several clinical trials evaluating DAPT. 3 -5 Recent trials have suggested no net clinical benefit of DAPT beyond 6-12 months after drug-eluting stent implantation, but all these trials had limited power to detect differences and did not include ACS patients exclusively. 6 -8 Although premature discontinuation of clopidogrel has been proved to be a major determinant of stent thrombosis, 9 -11 trials with newer generation drug-eluting stents have suggested low event rates despite a relatively short DAPT duration. 8, 12 Furthermore, results from register studies have suggested no apparent reduction of ischaemic adverse events when continuing clopidogrel treatment for .6 months. 13 Concerns about long-term antiplatelet treatment consist of increased costs and risk of bleeding with a low cost-benefit ratio. An overall decreased long-term risk of recurrent ischaemic events with newer generation drug-eluting stents, with more rapid neo-intimal coverage and improved implantation techniques, potentially limits the benefit of long-term DAPT. 14 The Swedish Websystem for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART) is a national register of all patients hospitalized for ACS in Sweden. 15 In order to evaluate the effect of different DAPT durations with clopidogrel and aspirin on clinical outcome in ACS patients, we analysed data from patients enrolled in the register from 2006 to 2010.
Methods
This study was a prospective observational cohort study using data from the SWEDEHEART and the Swedish National Board of Healthcare registries. The study was approved by the local Ethics Board and registered with clinicaltrials.gov (NCT01623700).
Patient selection and drug use
The national SWEDEHEART register includes patients with ACS from all Swedish hospitals and has since 2009 been integrated with the RIKS-HIA (Register of Information and Knowledge about Swedish Heart Intensive care Admissions); SCAAR (Swedish Coronary Angiography and Angioplasty Register); the Swedish Heart Surgery Register, and the National Register of Secondary Prevention (SEPHIA). Details about the register were described previously. 15 For vital status, date of death, incidence of myocardial infarction and stroke, and prescribed and dispensed medications, SWEDEHEART was then further merged with the National Cause of Death Register, National Patient Register, and the Prescribed Drug Register. The Swedish Prescribed Drug register holds information on each and every filled prescription at a Swedish pharmacy. Merging of the registries was performed by the Department of Statistics, Monitoring, and Evaluation, Epidemiologic Centre of the Swedish National Board of Health and Welfare and was approved by the Ethics Committee at Uppsala University.
Patients hospitalized for ST-elevation ACS (ST-ACS) or non-ST-elevation ACS (NST-ACS) between 1 January 2006 and 1 July 2010 were included in this study if they had filled prescriptions for DAPT with clopidogrel (75 mg once daily) and aspirin (75 mg once daily) after the event and if follow-up data were available for at least 1 year (Figure 1) . Patients with missing values for body mass index (BMI) and creatinine levels were excluded. According to local Swedish guidelines regulating the treatment duration, clopidogrel was generally prescribed for 3, 6, or 12 months. For the combined primary endpoint, treatment groups were defined according to dispensed clopidogrel tablets (t) and divided into 3 months' treatment (84-100 clopidogrel t) and .3 months' treatment (.100 t) groups. For the secondary endpoint analyses, the .3 month group was further divided into 6 months (168-200 t) or .6 months (.200 t) groups. Only patients naïve to clopidogrel, defined as no clopidogrel 180 days prior to the ACS event, and with clopidogrel dispensed from the pharmacy within 30 days of the ACS event were included. For the .3 vs. 3 months' DAPT outcome comparison, patients with any event of death, re-infarction, ischaemic or non-ischaemic stroke, stent Figure 1 Flow diagram of study population. ACS, acute coronary syndrome; NST-ACS, non-ST-elevation acute coronary syndrome; ST-ACS, ST-elevation acute coronary syndrome; ST, stent thrombosis; t, tablets; DAPT, dual antiplatlet treatment with clopidogrel and asprin. 
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Antiplatelet treatment duration in ACS thrombosis, coronary revascularization, or any clinically relevant bleeding occurring within the first 3 months after the index ACS event were excluded. This was because both ischaemic and bleeding events during this period would potentially interfere with the treating physician's initially determined antiplatelet treatment strategy. Correspondingly, for the .6 vs. 6 months comparison, patients with an event during the first 6 months were excluded.
Endpoints
The pre-defined primary endpoint was to analyse the effect of .3 months' vs. 3 months' DAPT duration on the combined clinical outcome: all-cause death, re-infarction, ischaemic or non-ischaemic stroke. Secondary endpoints included analyses of the effect of .6 months' vs. 6 months' DAPT on the combined endpoint as well as individual endpoints such as all-cause death, re-infarction, all coronary revascularizations, stroke, and bleeding. Appendix 1 lists the definitions of the pre-specified endpoint variables.
Statistical analyses
Univariate effects of DAPT duration groups (.3 months vs. 3 months and .6 months vs. 6 months) on the combined clinical endpoint of all-cause death, re-infarction, ischaemic or non-ischaemic stroke were evaluated using the Cox proportional hazard regression model. For the survival analyses, only the first occurrence of any of these events were counted. Logistic regression models with DAPT duration groups as response variables and age, sex, BMI, smoking status, ST-ACS/NST-ACS, number of days in hospital 3 years before index ACS, previous thrombolysis, medical history (cancer, dementia, chronic obstructive lung disease, bleeding, heart failure, ischaemic heart disease, atrial fibrillation, dialysis, renal failure, stroke, diabetes, intestinal disease, peripheral vascular disease, hypertension, hyperlipidaemia, revascularization, angiography, stent thrombosis) and drug history (aspirin, warfarin, statin, ACE-inhibitor, betablocker, proton pump inhibitor, calcium channel blocker) as covariates were used to estimate two different propensity scores, one for the .3 months vs. 3 months comparison and another for the .6 months vs. 6 months comparison. The estimated propensity scores were normalized and used as inverse probability of treatment weights in the adjusted models. The adjusted ps-weighted Cox proportional hazard regression models included the covariates of revascularization during the acute phase, number of implanted stents, drug-eluting stent, year of enrolment, creatinine clearance, hospital, insulin (5 years before MI), and on-going medication (ACE-inhibitor, statin, warfarin, beta-blocker, calcium channel blocker, oral diabetic, proton pump inhibitor).
In the survival analyses of the combined primary endpoint (death/ stroke or re-infarction), patients were censored during the follow-up for bleeding, stent thrombosis, and revascularization events. For the survival analyses of the individual endpoints of bleeding, re-infarction, revascularization, and stroke, patients who died during follow-up were censored and for the analyses of all-cause death, patients were only censored for end of follow-up. We used the Charlson Index to measure comorbidity. 16 The Charlson Index includes 19 diseases that have been selected and weighted on the basis of the strength of their association with mortality. For the estimation of bleeding risk in treatment groups, the Reduction in Atherothrombosis for Continued Health (REACH) bleeding risk score was calculated. The risk score was developed from the REACH registry, into a nine-item point scheme to evaluate the 2-year risk of serious bleeding. 17 The risk factors included in both scores were included in the statistical models controlling for confounders. Statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC, USA) and R version 2.14.1.
Results Demographics
similar between groups. Patients with longer treatment duration were more likely to have had a previous revascularization, insulin-treated diabetes, to have received a drug-eluting stent, and to have undergone a more complex percutaneous coronary intervention for the index event (more stents, longer stents). Atrial fibrillation and previous warfarin treatment were less likely in longer treatment duration groups compared with the 3-month treatment duration group. The on-going medication was typical for a contemporary ACS population with .90% of patients on beta-blockers and statins, .80% of patients on ACE-inhibitors and 40% of patients using proton pump inhibitors.
Hospital course during index hospitalization and treatment duration (Figure 2A ). For the 6 and .6 months' treatment groups, the corresponding median treatment durations were 200 (Q1 ¼ 200 and Q3 ¼ 200) and 400 (Q1 ¼ 300 and Q3 ¼ 400) days, respectively ( Figure 2B ).
Comorbidity and risk factors for bleeding
To measure comorbidity and bleeding risk in the treatment groups, the Charlson comorbidity index and the REACH bleeding risk score were calculated. Although absolute differences were small, patients with longer treatment durations tended to have higher comorbidity and bleeding risk ( Figure 4) . After adjusting for differences in baseline characteristics, the hazard ratio remained statistically significant [adjusted HR 0.75 with 95% CI (0.59-0.95); P ¼ 0.0155]. The lower event rate with longer treatment duration remained statistically significant after adjustment for the subgroup of patients revascularized at the index event but not for those that were not ( Table 5) . For the combined endpoint of all-cause death, stroke, or re-infarction, the interactions between DAPT duration and revascularized at index for the comparisons .3 vs. 3 months' and .6 vs. 6 months' were statistically significant (P ¼ 0.002 and P ¼ 0.002, respectively).
Individual endpoints
For the individual endpoint of re-infarction, there was a statistically significant lower event rate with . In the analyses of revascularization as an event post-ACS, the . 3 vs. 3 months' DAPT duration was associated with a higher hazard ratio [adjusted HR 1.37 with 95% CI (1.21-1.56); P , 0.0001]. The largest difference in revascularization rate between the .3 vs. 3 months' DAPT groups was seen in patients who did not undergo during the index hospitalization [adjusted HR 2.02 with 95% CI (1.52-2.69); P , 0.0001 vs. 1.20, with 95% CI (1.03-1.38); P ¼ 0.017 for patients who did not undergo revascularization at the index hospitalization and those who did, respectively]. For the .6 vs. 6 months' treatment groups, there was no difference in revascularization rates (data not shown). 
Bleeding events
The risk of bleeding was higher in treatment groups with longer DAPT duration [.3 vs. 3 months' adjusted HR 1.56, 95% CI (1.18-2.07); P ¼ 0.0018] (Table 4, Figure 5 unadjusted data). Reported bleeds (316 vs. 180 in .3 and 3 months', respectively) were most commonly distributed into gastrointestinal bleeds (e.g. gastric and duodenal ulcers with haemorrhage) (76.1% of bleeds), intracranial bleeds (e.g. intracerebral and subarachnoid haemorrhage) (12.9%), and non-specified post-haemorrhagic anaemia (10.3%). The calculated incidence of bleeding was 11 events per 1000 person-years in the .3 months' DAPT group compared with eight events per 1000 person-years in the 3 months' DAPT group. For bleeding, the interaction between DAPT and revascularized at index for the comparison .3 vs. 3 months' was not significant (P ¼ 0.38).
Discussion
This is, to our knowledge, the largest outcome analysis of varying DAPT durations in patients discharged from hospital with ACS. .......... ............ ............ ............ ........... ............ ............ ............ ........... ............ ............ ............ ........... ............ .... ..... Our data show that clopidogrel co-administered with aspirin for .3 months compared with 3 months was associated with a statistically significantly lower incidence of death/stroke or re-infarction in patients post-ACS. Baseline characteristics, as well as comorbidity and overall bleeding risk were similar between treatment groups, indicating a similar background for ischaemic and bleeding risk in treatment groups.
In the analyses, we excluded patients with events that occurred within the first 3 months of the index event during which the antiplatelet treatment was the same in the DAPT duration groups, since events during that period were likely to interfere with and alter the initial treatment duration strategy, either by interruption due to bleeding events or prolongation due to ischaemic events. Therefore, it is unlikely that the treatment duration effect is influenced by the early risk hazard associated with an unsuspected event that would change the initial treatment strategy. Also for the individual endpoints of myocardial infarction and death, there tended to be lower event rates with a prolonged treatment duration .3 months. For myocardial infarction, this difference reached statistical significance. The observed consistency between these outcome measures, with a lower event rate with the .3 month treatment duration, also strengthens the conclusion of a lower ischaemic event rate after the initial 3 months of treatment. However, in contrast to the ischaemic endpoints of death and MI, repeat revascularizations occurred more frequently in the .3 month DAPT group compared with the 3-month group. This difference was mostly driven by the fact that patients who were not revascularized during the index event, underwent revascularization later in time leading to prolongation of the DAPT.
The potentially negative consequence of prolonged antiplatelet treatment is increased bleeding risk. In our study, bleeding was more common in groups with longer treatment duration. This is consistent with previous findings that DAPT duration correlates with the risk of bleeding, 6 ,18 which in turn negatively influences outcomes after coronary stenting. 19 Recently, several independent but moderately large trials have suggested that a shorter DAPT duration after stent placement may be as beneficial as longer duration. 6 -8,20 An extended clopidogrel therapy .12 months in patients after implantation of drug-eluting stents did not reduce myocardial infarction or death. 7 Similarly, shortening DAPT duration to 6 vs. 12 months after drug-eluting stenting did not increase the combined endpoint of cardiac death, myocardial infarction, and ischaemia-driven target vessel revascularization in the EXCELLENT (Efficacy of Xience/Promus Versus Cypher in Reducing Late Loss After Stenting) study. 8 Finally, 24 months of DAPT after drug-eluting and bare metal stenting was no more effective in reducing ischaemic events that 6 months in the in the Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY). 6 In summary, a limited sample size and the inclusion of mainly low-risk patients with low event rates in these trials make conclusions about the safety of short-term DAPT uncertain. Three larger randomized trials evaluating the effects of DAPT duration are on-going. First, The Safety And Efficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) will 21 and secondly, The Optimized Duration of clopidogrel therapy following treatment with the endeavor zotarolimus-eluting stent in real-world clinical practice (OPTIMIZE) trial will evaluate 3 months vs. 12 months DAPT. 22 Lastly, the Dual Antiplatelet Therapy (DAPT) study aims to compare 12 vs. 30 months of DAPT in preventing cardiovascular events in subjects undergoing PCI with drug-eluting stents. 23 After 12 months of DAPT, and exclusion of patients with major ischaemic or bleeding events during that time, patients will be randomized to either placebo or continued DAPT up to 30 months. The study allows different stent types and either clopidogrel or prasugrel at the investigator's discretion but no analyses of those features are planned. Therefore, this trial's major limitation is the fact that the potential differential effects on stent thrombosis or bleeding of clopidogrel and prasugrel will not be examined. Our study has important possible limitations. The DAPT duration was defined using information on number of dispensed tablets, and not on those actually ingested. It is possible that some patients with small quantities of clopidogrel dispensed (only one dispensing occasion), in the 3 months' treatment group, tended to be less compliant with treatment than those with larger quantities dispensed (which normally requires at least a second filling of a prescription). This could possibly lead to an overestimation of the positive effect of longer treatment, since patients who were in reality partly untreated, were used as comparators. We cannot exclude the possibility that factors associated with longer DAPT duration, such as repeat revascularization, also contributed to increased bleeding in the .3-month treatment duration group. Despite adjusting for propensity scores including a high number of variables, the possibility remains that the treatment groups were different due to unknown confounders. Nonetheless, our study conclusions are strengthened by the fact that data collection was independent of both treatment and outcome.
In conclusion, in this large study of a contemporary, real-life ACS population, a DAPT duration of .3 months compared with a shorter treatment duration was associated with a reduction of the composite outcomes of death, re-infarction, or stroke. Solutions; Honoraria from The Medicines Company, AstraZeneca, Eli Lilly, Bristol-Myers Squibb, Sanofi, and IROKO; consultant/advisory board fees from AstraZeneca, Eli Lilly, Merck, Medtronic, and Sanofi.
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